Yourgene Health PLC Change of Name to Yourgene Health plc (5273G)
November 07 2018 - 2:00AM
UK Regulatory
TIDMYGEN
RNS Number : 5273G
Yourgene Health PLC
07 November 2018
Premaitha Health plc
("Premaitha" or the "Group")
Change of Name to Yourgene Health plc
&
Change of Website Address
Manchester, UK - 7 November 2018: Premaitha Health plc, the
international molecular diagnostics group which commercialises
genetic products and services that positively impact human health,
is pleased to confirm the renaming of the Group as Yourgene Health
plc ("Yourgene Health").
Further to the special resolution approved at the Group's Annual
General Meeting on 25 October 2018, the Group's name has been
changed to Yourgene Health plc and trading in the Group's shares
under the new name and TIDM, "YGEN", will commence at 8.00 a.m.
today. The Group's website is now available at
www.yourgene-health.com.
The change of name reflects the Group's broadened product
development and research service capabilities which extend across
the lifecycle of DNA test development and commercialisation.
Yourgene Health's ongoing strategic priorities include:
-- developing and commercialising genetic products and services
that positively impact human health;
-- driving worldwide sales of the Group's non-invasive prenatal
testing ("NIPT") products and services by targeting further
expansion through direct and key distribution channels to expand
the geographic footprint;
-- continuing to offer highly customer-focused NIPT products and
services which support all types of customer - irrespective of
size, geography and market maturity - in partnership with leading
DNA technology providers;
-- leveraging the Group's technical and regulatory expertise and
partnerships to extend its genetic testing offering into
complementary areas of reproductive health and oncology, both with
owned intellectual property and as a third-party collaborator;
and
-- supporting diagnostic majors and bioinformatics specialists
with in vitro diagnostic product contract development
partnerships.
Shareholdings will be unaffected by the change of name and
existing share certificates should be retained as they will remain
valid for all purposes. Any new share certificates issued will bear
the name Yourgene Health plc.
Lyn Rees, Chief Executive Officer of Yourgene Health, commented:
"Our change of name to Yourgene Health marks the beginning of an
exciting new period for the Group. It reflects our broadened
capabilities within the genetic testing universe and the combining
of the Premaitha and Yourgene Bioscience businesses.
"Within the NIPT segment, we are aggressively targeting further
expansion through distribution and licensing partnerships. The
consolidated Group is now well-placed to deliver services to a
global market and maximise its revenue potential.
"Our technical expertise in genetic test development,
partnerships with DNA technology majors and expanding global
footprint also put us in a strong position to develop additional
products both within reproductive health and oncology.
"I look forward to providing further updates on the
commercialisation of the Group as we expand organically, through
distribution and licensing agreements, and via third party
partnerships."
For more information, please contact:
Yourgene Health plc Tel: +44 (0)161
Lyn Rees, Chief Executive Officer 667 1053
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
investors@yourgene-health.com
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213
Liam Murray / James Caithie 0880
finnCap (Broker) Tel: +44 (0)20 7220
Geoff Nash / Matthew Radley (Corporate Finance) 0500
Tim Redfern (Corporate Broking)
Vigo Communications Tel: +44 (0)20 7390
Ben Simons / Fiona Henson / Antonia Pollock 0234
yourgene@vigocomms.com
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services
that positively impact human health. The group works in partnership
with global leaders in DNA technology to advance diagnostic
science.
Our product development and research service capabilities extend
across the lifecycle of DNA test development including regulatory
submissions.
Yourgene Health's first commercialised products are non-invasive
prenatal tests (NIPT) for Down's syndrome and other genetic
disorders, targeting a share of an emerging billion-dollar global
market.
Prenatal screening is an established clinical practice, but
accuracy challenges with traditional methods are driving the need
for NIPT and other DNA-based reproductive health testing solutions.
Yourgene Health's customer-focused products and services support
all types of customer, irrespective of size, geography and market
maturity. Our commercial footprint is already established in the
UK, Europe, the Middle East, Africa and Asia.
Through our technical expertise and partnerships, Yourgene
Health is aiming to extend its genetic testing offering into
complementary areas of reproductive health and oncology.
Yourgene Health is headquartered in Manchester, UK with
facilities in Taipei and Singapore. For more information visit
www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CANBSBDBBUGBGIL
(END) Dow Jones Newswires
November 07, 2018 02:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024